OBJECTIVE: Activated protein C (APC) is neuroprotective in stroke models and promotes postischemic neovascularization and neurogenesis. We used a controlled cortical impact (CCI) in mice to determine the effects of APC on neuroprotection and angiogenesis and neurogenesis after traumatic brain injury (TBI). METHODS: Mice were given (1) single-dose APC (0.8 mg/kg intraperitoneally) 15 minutes after injury, (2) multidose APC (0.8 mg/kg intraperitoneally) 15 minutes and 6 to 48 hours after injury, or (3) vehicle. We then assessed the effects of APC on posttraumatic motor function with the rotarod and wire grip and beam balance tasks, and we determined the lesion volumes and studied the formation of new blood vessels and markers of neurogenesis. RESULTS: Mice treated with single-dose or multidose APC, compared with vehicle, showed significantly improved motor function on all tests. In the single-dose and multidose APC treatment groups, at 7 days after treatment, lesion volume was significantly decreased by 30% and 50%, respectively. Multidose APC, but not single-dose APC, increased new blood vessel formation as shown by CD105(+)/Ki-67(+) double immunostaining by nearly 2-fold at 7 days. Multidose APC also promoted posttraumatic proliferation of neuroblasts in the subventricular zone (SVZ) and their migration from the SVZ to the perilesional area. CONCLUSION: Activated protein C improves functional outcome and is neuroprotective after TBI. It also promotes angiogenesis and survival and migration of neuroblasts from the SVZ to the perilesional area, but the exact role of these brain repair mechanisms remains to be determined. The present findings suggest that APC therapy may hold a significant therapeutic potential for TBI.
OBJECTIVE:Activated protein C (APC) is neuroprotective in stroke models and promotes postischemic neovascularization and neurogenesis. We used a controlled cortical impact (CCI) in mice to determine the effects of APC on neuroprotection and angiogenesis and neurogenesis after traumatic brain injury (TBI). METHODS:Mice were given (1) single-dose APC (0.8 mg/kg intraperitoneally) 15 minutes after injury, (2) multidose APC (0.8 mg/kg intraperitoneally) 15 minutes and 6 to 48 hours after injury, or (3) vehicle. We then assessed the effects of APC on posttraumatic motor function with the rotarod and wire grip and beam balance tasks, and we determined the lesion volumes and studied the formation of new blood vessels and markers of neurogenesis. RESULTS:Mice treated with single-dose or multidose APC, compared with vehicle, showed significantly improved motor function on all tests. In the single-dose and multidose APC treatment groups, at 7 days after treatment, lesion volume was significantly decreased by 30% and 50%, respectively. Multidose APC, but not single-dose APC, increased new blood vessel formation as shown by CD105(+)/Ki-67(+) double immunostaining by nearly 2-fold at 7 days. Multidose APC also promoted posttraumatic proliferation of neuroblasts in the subventricular zone (SVZ) and their migration from the SVZ to the perilesional area. CONCLUSION:Activated protein C improves functional outcome and is neuroprotective after TBI. It also promotes angiogenesis and survival and migration of neuroblasts from the SVZ to the perilesional area, but the exact role of these brain repair mechanisms remains to be determined. The present findings suggest that APC therapy may hold a significant therapeutic potential for TBI.
Authors: J Andrew McKee; Randall P Brewer; Gary E Macy; Cecil O Borel; James D Reynolds; David S Warner Journal: Neurocrit Care Date: 2005 Impact factor: 3.210
Authors: Rui Lan Zhang; Yvonne LeTourneau; Sara R Gregg; Ying Wang; Yier Toh; Adam M Robin; Zheng Gang Zhang; Michael Chopp Journal: J Neurosci Date: 2007-03-21 Impact factor: 6.167
Authors: Berislav V Zlokovic; Chunling Zhang; Dong Liu; Jose Fernandez; John H Griffin; Michael Chopp Journal: Ann Neurol Date: 2005-09 Impact factor: 10.422
Authors: Tong Cheng; Anthony L Petraglia; Zhang Li; Meenakshisundaram Thiyagarajan; Zhihui Zhong; Zhenhua Wu; Dong Liu; Sanjay B Maggirwar; Rashid Deane; José A Fernández; Barbra LaRue; John H Griffin; Michael Chopp; Berislav V Zlokovic Journal: Nat Med Date: 2006-10-29 Impact factor: 53.440
Authors: Ye Xiong; Asim Mahmood; Yuling Meng; Yanlu Zhang; Zheng Gang Zhang; Daniel C Morris; Michael Chopp Journal: J Neurosurg Date: 2010-05-21 Impact factor: 5.115
Authors: Laurent Burnier; Amin Boroujerdi; Jose A Fernández; Jennifer V Welser-Alves; John H Griffin; Richard Milner Journal: Exp Neurol Date: 2016-07-10 Impact factor: 5.330
Authors: Arun Paul Amar; Abhay P Sagare; Zhen Zhao; Yaoming Wang; Amy R Nelson; John H Griffin; Berislav V Zlokovic Journal: Neuropharmacology Date: 2017-09-18 Impact factor: 5.250
Authors: Kassandra Kisler; Divna Lazic; Melanie D Sweeney; Shane Plunkett; Mirna El Khatib; Sergei A Vinogradov; David A Boas; Sava Sakadži; Berislav V Zlokovic Journal: Nat Protoc Date: 2018-05-24 Impact factor: 13.491